Hikma Pharmaceuticals Plc Total Voting Rights (2759C)
June 27 2016 - 2:00AM
UK Regulatory
TIDMHIK
RNS Number : 2759C
Hikma Pharmaceuticals Plc
27 June 2016
Hikma Pharmaceuticals PLC
Voting Rights and Capital
LONDON, 27 June 2016, Hikma Pharmaceuticals PLC (LSE: HIK)
(NasdaqDubai: HIK) notifies the market that its capital consists of
239,923,850 ordinary shares with voting rights. There are nil
shares held in treasury.
The above figure may be used by shareholders as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, Hikma Pharmaceuticals PLC under the FCA's Disclosure and
Transparency Rules.
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary +44 20 7399 2760
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2015, Hikma achieved
revenues of $1,440 million and profit attributable to shareholders
of $252 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVREALKSASAKEFF
(END) Dow Jones Newswires
June 27, 2016 02:00 ET (06:00 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024